Martin Hutchings, MD, PhD from Copenhagen University Hospital, Copenhagen, Denmark, discusses current first-line treatment options in Hodgkin lymphoma at the European Blood and Marrow (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal. He also speaks about novel agent therapies, and their potential for changing the treatment landscape in the future.
Current landscape and future prospects for Hodgkin lymphoma treatment
